IRIS
ADAMO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.646
EU - Europa 5.944
AS - Asia 1.257
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
SA - Sud America 5
AF - Africa 3
Totale 13.872
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.626
IE - Irlanda 1.614
SE - Svezia 1.582
CN - Cina 958
IT - Italia 639
UA - Ucraina 483
PL - Polonia 467
DE - Germania 344
FI - Finlandia 253
GB - Regno Unito 210
FR - Francia 171
SG - Singapore 136
IN - India 83
BE - Belgio 71
VN - Vietnam 50
AT - Austria 39
RU - Federazione Russa 22
CA - Canada 19
CZ - Repubblica Ceca 11
EU - Europa 8
IR - Iran 8
JP - Giappone 8
ES - Italia 6
AU - Australia 5
HR - Croazia 5
CH - Svizzera 4
HK - Hong Kong 4
NL - Olanda 4
LV - Lettonia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CL - Cile 2
IL - Israele 2
LU - Lussemburgo 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
RO - Romania 2
TH - Thailandia 2
ZA - Sudafrica 2
AL - Albania 1
AR - Argentina 1
BR - Brasile 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
ID - Indonesia 1
IQ - Iraq 1
KZ - Kazakistan 1
LT - Lituania 1
MA - Marocco 1
MM - Myanmar 1
MX - Messico 1
NO - Norvegia 1
RS - Serbia 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 13.872
Salva come PNG Salva come JPEG
Città #
Dublin 1.612
Chandler 1.368
Jacksonville 1.009
Nyköping 843
Warsaw 464
Beijing 410
Ashburn 345
New York 281
Ann Arbor 277
Princeton 271
Medford 258
Dearborn 250
Cambridge 240
Des Moines 208
Boardman 164
Messina 136
Woodbridge 84
Jinan 83
Singapore 77
Brussels 70
Lancaster 70
Wilmington 59
Pune 56
Shenyang 54
San Mateo 53
Los Angeles 49
Dong Ket 46
Nanjing 42
Vienna 39
Tianjin 37
Hebei 34
Zhengzhou 33
Houston 27
Haikou 25
Hangzhou 23
Seattle 23
Nanchang 21
Changsha 19
Leawood 19
Ningbo 19
Jiaxing 18
Taizhou 18
Guangzhou 17
Milan 16
Helsinki 15
Hyderabad 15
Taiyuan 15
Grammichele 14
Washington 14
Fort Washington 13
Fuzhou 13
Lanzhou 13
Norwalk 13
Bremen 11
Augusta 10
London 10
Rome 10
Monmouth Junction 9
Clearwater 8
Falls Church 8
Modica 8
Brno 6
Edinburgh 6
Saint Petersburg 6
Santa Clara 6
Tappahannock 6
Toronto 6
Ardabil 5
Catania 5
Kunming 5
Montréal 5
Ottawa 5
Shenzhen 5
Auburn Hills 4
Brescia 4
Colombes 4
Hong Kong 4
Kemerovo 4
La Spezia 4
Lappeenranta 4
Las Vegas 4
Mumbai 4
Napoli 4
Olomouc 4
Redwood City 4
Tokyo 4
Bari 3
Brockport 3
Hanoi 3
Hefei 3
Madrid 3
Mountain View 3
Novi 3
Novokuznetsk 3
Radomsko 3
Redmond 3
Reggio Calabria 3
San Francisco 3
San Giovanni Rotondo 3
Sassari 3
Totale 9.626
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 363
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 126
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 117
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 102
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 93
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 90
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 89
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 87
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 84
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 83
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 82
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 82
NSCLC and HER2: between lights and shadows 82
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 81
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 81
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 80
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 80
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 80
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 79
The Mam-1 GOCSI Trial: a Randomised Trial with Factorial Design of Chemo-Endocrine Adjuvant Treatment in Node-Positive (N+) Early Breast Cancer (EBC). 79
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 79
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 78
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 77
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 76
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 75
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 75
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 75
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 75
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 74
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 74
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 73
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 73
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 73
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. 72
[Serum levels of copper and zinc in patients with lung cancer] 72
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 72
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 71
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 71
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 70
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 70
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 70
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 69
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 69
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 68
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 68
The treatment of peritoneal carcinomatosis in elderly patients. 68
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 68
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 68
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 68
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 68
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 67
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 66
Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer 66
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 66
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 66
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 66
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 66
I Tumori del coloretto. La chemioterapia della fase avanzata. 65
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 65
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 65
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 65
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 64
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 64
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 64
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 64
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 64
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 64
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 64
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 63
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 63
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 63
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 62
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 62
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 62
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 62
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 62
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 61
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 61
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 61
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 61
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 61
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery 60
Peritoneal carcinomatosis of colorectal origin. 60
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 60
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 59
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 59
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 59
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 59
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 59
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 59
Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial 59
Breast. La terapia primaria: stato dell'arte 58
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 58
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 57
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 57
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 57
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 57
Phase II trial ZD1839(IRESSA)second-third line in patients with advanced/metastatic non small cell lung cancer (NSCLC):preliminary results 56
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 56
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 56
Totale 7.279
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.367
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.367
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.602 0 0 28 101 23 262 250 239 49 257 330 63
2020/20212.239 224 48 416 221 205 223 115 159 65 238 193 132
2021/20221.767 19 244 30 45 58 16 104 64 15 318 264 590
2022/20235.002 388 490 215 417 381 512 80 328 1.976 19 140 56
2023/20241.291 100 185 70 107 67 495 66 56 5 46 11 83
2024/2025146 66 47 33 0 0 0 0 0 0 0 0 0
Totale 14.148